Concord Wealth Partners Veracyte, Inc. Transaction History

Concord Wealth Partners

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	BUY	$15.31 - $29.94 $1,056 - $2,065	69 New	69 $1,000
Q2 2022 Aug 04, 2022	SELL	$15.45 - $29.52 $1,838 - $3,512	-119 Closed	0 $0
Q1 2022 Apr 20, 2022	BUY	$21.94 - $42.51 $87 - $170	4 Added 3.48%	119 $3,000
Q4 2021 Jan 21, 2022	BUY	$36.09 - $53.79 $3,212 - $4,787	89 Added 342.31%	115 $5,000
Q3 2021 Nov 09, 2021	BUY	$35.62 - $52.97 $35 - $52	1 Added 4.0%	26 $1,000
Q2 2021 Jul 29, 2021	BUY	$32.94 - $56.62 $329 - $566	10 Added 66.67%	25 $1,000
Q4 2020 Feb 16, 2021	BUY	$32.49 - $61.88 $487 - $928	15 New	15 $1,000

316

81.8M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.23B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.